Filing Flows

Filing Flows › Companies › China Pharma Holdings › Cash flow

China Pharma Holdings cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$33K in Q2 2026 · −$140K over twelve months

Operating cash flow−$33K
Free cash flow−$33K
Cash conversion cycle86 days

Analysis

In Q2 2026, China Pharma Holdings generated −$33K of operating cash flow. That is $307K less than in Q2 2025 ($274K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$140K; the largest uses were net borrowing (+) / repaid (−) ($163K), operating cash flow ($140K); besides operations, cash came from other financing ($9K); the cash balance fell by $320K.

Operating cash flow was −$33K against net income of −$1.5M. The largest differences: depreciation & amortization +$1.1M, inventory +$273K, receivables −$151K.

Its cash conversion cycle was 86 days (receivables 18 + inventory 151 − payables 83).

Free cash flow

China Pharma Holdings: free cash flow by quarterChina Pharma Holdings: free cash flow by quarter−$38KQ3 2024$279KQ4 2024−$132KQ1 2025$274KQ2 2025−$205KQ3 2025$152KQ4 2025−$55KQ1 2026−$33KQ2 2026
Operating cash flow less capital spending.
China Pharma Holdings: operating cash flow against capital spendingChina Pharma Holdings: operating cash flow against capital spendingOperating cash flowCapital spending−$47K−$9KQ3 2024$299K$20KQ4 2024−$74K$58KQ1 2025$274K−$65Q2 2025−$204K$1KQ3 2025$152K$454Q4 2025−$55K$0Q1 2026−$33K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$33K, Capital spending $0.

Capital allocation, year by year

China Pharma Holdings: where the cash came from (up) and went (down), by fiscal yearChina Pharma Holdings: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$250KFY2021: Net borrowing −$1.2MFY2021: Shares issued $5.0MFY2021: Capital spending −$438K$5.0MFY2021FY2022: Operating cash flow −$410KFY2022: Net borrowing −$2.1MFY2022: Capital spending −$402KFY2022FY2023: Operating cash flow −$700KFY2023: Net borrowing $43KFY2023: Capital spending −$12K$43KFY2023FY2024: Operating cash flow −$406KFY2024: Net borrowing −$61KFY2024: Capital spending −$38KFY2024FY2025: Operating cash flow $148KFY2025: Net borrowing −$555KFY2025: Capital spending −$59K$148KFY2025
Over these 5 years operating cash flow totalled −$1.6M; the largest uses were net borrowing ($4.0M) and operating cash flow ($1.8M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$305K
Debt$1.6M
Net debt$1.3M
Cash runway2.2 years

China Pharma Holdings is burning cash: its operations consume cash, a free cash flow of −$140K a year at the current rate against $305K of cash and investments: a runway of about 2.2 years before any new financing.

Where the cash came from and went

China Pharma Holdings: sources (+) and uses (−) of cash, Q2 2026China Pharma Holdings: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)−$136KOther financing$121KExchange rates$49KOperating cash flow−$33KNet borrowing (+) / repaid (−)−$1K
China Pharma Holdings: sources (+) and uses (−) of cash, TTM to Q2 2026China Pharma Holdings: sources (+) and uses (−) of cash, TTM to Q2 2026Cash drawn (+) / kept (−)$320KNet borrowing (+) / repaid (−)−$163KOperating cash flow−$140KNot reconciled−$79KExchange rates$53KOther financing$9K

From profit to cash

China Pharma Holdings: net income to operating cash flow, Q2 2026China Pharma Holdings: net income to operating cash flow, Q2 2026Net income−$1.5MDepreciation & amortization$1.1MGains on disposals$2KReceivables−$151KInventory$273KPayables−$116KDeferred revenue$89KOperating cash flow−$33K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 2026181518386
Q1 202620201111110
Q4 2025171406394
Q3 20253018863155
Q2 20252715044132
Q1 20252215027145
Q4 20242316922170
Q3 20242515115161

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q2 2026−$33K—−$1K−$136K−$33K
Q1 2026−$55K—−$158K$177K−$55K
Q4 2025$152K−$454−$701K−$77K$152K
Q3 2025−$204K−$1K$618K$357K−$205K
Q2 2025$274K$65−$1.0M−$212K$274K
Q1 2025−$74K−$58K−$77K$214K−$132K
Q4 2024$299K−$20K—$92K$279K
Q3 2024−$47K$9K—$21K−$38K

China Pharma Holdings: income statement and cash flow

China Pharma Holdings, Q2 2026: revenue $948K (-8% year over year), operating margin -151.0%. The chart follows the revenue to costs, profit and cash.

China Pharma Holdings: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.